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Abstract
Kenya introduced the monovalent Rotarix® rotavirus group ABackground: 
(RVA) vaccine nationally in mid-2014.  Long-term surveillance data is important
prior to wide-scale vaccine use to assess the impact on disease and to
investigate the occurrence of heterotypic strains arising through immune
selection. This report presents baseline data on RVA genotype circulation
patterns and intra-genotype genetic diversity over a 7-year period in the
pre-vaccine era in Kilifi, Kenya, from 2002 to 2004 and from 2010 to 2013.
A total of 745 RVA strains identified in children admitted with acuteMethods: 
gastroenteritis to a referral hospital in Coastal Kenya, were sequenced using
the di-deoxy sequencing method in the VP4 and VP7 genomic segments
(encoding P and G proteins, respectively). Sequencing successfully generated
569 (76%) and 572 (77%) consensus sequences for the VP4 and VP7 genes
respectively. G and P genotypes were determined by use of BLAST and the
online RotaC v2 RVA classification tool.
The most common GP combination was G1P[8] (51%), similar to theResults: 
Rotarix® strain, followed by G9P[8] (15%) , G8P[4] (14%) and G2P[4] (5%).
 Unusual GP combinations—G1P[4], G2P[8], G3P[4,6], G8P[8,14], and
G12P[4,6,8]—were observed at frequencies of <5%. Phylogenetic analysis
showed that the infections were caused by both locally persistent strains as
evidenced by divergence of local strains occurring over multiple seasons from
the global ones, and newly introduced strains, which were closely related to
global strains. The circulating RVA diversity showed temporal fluctuations both
season by season and over the longer-term. None of the unusual strains
increased in frequency over the observation period.  
The circulating RVA diversity showed temporal fluctuations withConclusions: 
several unusual strains recorded, which rarely caused major outbreaks.  These
data will be useful in interpreting genotype patterns observed in the region
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 data will be useful in interpreting genotype patterns observed in the region
during the vaccine era.
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Introduction
Rotavirus group A (RVA) infection is a leading cause of child-
hood severe dehydrating acute diarrhoea, which can lead to 
death1. The 2016 estimates show that, annually, RVA is responsi-
ble for 128,500 deaths globally, with the highest burden occurring 
in sub-Saharan Africa and South-East Asia countries2. In 2009, 
the World Health Organization (WHO) recommended the inclu-
sion of either of the two licensed RVA vaccines (Rotarix® and 
RotaTeq®) into national immunization programmes (NIPs) of all 
countries to curb RVA associated disease burden3. Kenya intro-
duced the monovalent Rotarix® vaccine (based on the G1P[8] 
strain) into its NIP in July 20144.
In Africa, the introduction of the Rotarix® vaccine into the NIPs 
of several countries has been associated with a marked reduc-
tion in hospitalization caused by RVA infection5,6. For instance 
in Malawi, Burkina Faso and Tanzania, the vaccine effective-
ness against hospitalization was estimated at 62%, 58% and 
53%, respectively7. However, this effectiveness is lower than that 
observed in developed countries; for example in Belgium, vac-
cine effectiveness of Rotarix vaccine was estimated at 90%8. 
Furthermore, concerns remain that in time, given the high diver-
sity of RVA strains, vaccine immunity escape variants could 
emerge which may undermine the gains from the vaccination 
programmes9. Such a scenario was observed in Japan where, a 
G8P[8] RVA strain appeared to emerge and caused acute gas-
troenteritis disease in up to 66% (53/80) of children attending 
a pediatric clinic10. Similarly, the predominance of non-vac-
cine type G2P[4] strains was observed in Rotarix® vaccinated 
populations of Belgium11 and Brazil12, raising concerns of the 
effect of the vaccine on circulating non-vaccine strains. 
The rotavirus genome is comprised of 11 segments of dou-
ble-stranded RNA, which encode 12 proteins (VP1-4, VP6, 
VP7, NSP1-6). The VP7 and VP4 proteins independently elicit 
neutralizing antibodies and specify the G (glycoprotein) and 
P (protease-sensitive) genotypes, respectively13. Molecular char-
acterization of the VP7 and VP4 proteins encoding regions is 
commonly used to investigate local and global RVA molecular 
epidemiology and is the basis of the dual genotype classifica-
tion of this virus14. Up to 36 different G and 51 P RVA geno-
types have been identified worldwide in humans and animals15. 
Globally, G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] (in 
decreasing order) have been identified as the most common 
genotypes causing disease in children, although their distribu-
tion can vary considerably from region to region and from one 
season to the next16,17. While these genotypes are similarly domi-
nant in Africa18, understanding of their local natural seasonal 
fluctuations and intra-genotype diversity in the pre-vaccine 
introduction era is incomplete despite importance to vaccine 
impact evaluation.
The current study presents molecular analysis of historical 
RVA strains from coastal Kenya detected between 2002–2004, 
reported in Nokes et al.19, which we refer to as phase 1, together 
with more recent RVA strains detected between 2010–2013, 
referred to as phase II. We present findings from partial sequence 
analysis of these longitudinally collected RVA strains identified 
at the Kilifi County Hospital (KCH), Kilifi, Kenya, and phyloge-
netically compare these with those deposited in public databases 
across the globe. The typing of phase I strains was previously 
performed by nested multiplex PCR using genotype-specific 
VP7 and VP4 primers19. We utilize these extensive sequence data 
to illuminate on local RVA genotype circulation characteristics 
and provide baseline information on natural patterns of RVA 
genotype diversity in coastal Kenya prior to vaccine introduction.
Methods
RVA surveillance in Kilifi County Hospital
RVA surveillance in KCH reported in this analysis was con-
ducted from January 2002 to December 2004, and from January 
2010 to December 2013. Study subject recruitment criteria and 
sample collection methods are as previously described19. The 
study targeted children aged less than 13 years admitted with 
acute diarrhoea defined as three or more watery stools passed 
during a 24-hour period20. The KEMRI Scientific and Ethics 
Review Unit (SERU) in Kenya approved the study protocol.
Detection of RVA
Stool samples were screened for RVA using an enzyme immu-
noassay (EIA) kit, marketed under two different names in 
the two periods: IDEIA (DAKO Rotavirus IDEIATM, Oxoid, 
Ely, United Kingdom) in phase I and ProSpectTM (Oxoid, 
Basingstoke UK) in phase II, following the manufacturer’s 
instructions.
Partial sequencing of RVA positive samples in VP4 and 
VP7 segments
Sequencing was conducted on 272 (46%) of 558 positive samples 
detected in phase I, and all positive samples identified in phase 
II (n=473). The phase I samples were selected to represent com-
mon RVA genotypes (>70%) observed throughout the surveil-
lance period from each year. Partial fragments of the VP4 and 
VP7 genes, were amplified in a one-step reverse transcriptase 
PCR reaction using the following primer pairs: VP4F, 5’-TAT-
GCTCCAGTNAATTGG-3’, VP4R 5’-ATTGCATTTCTTTC-
CATAATG-3’, VP7F, 5’-ATGTATGGTATTGAATATACCAC-3’, 
VP7R 5’–-AACTTGCCACCATTTTTTCC-3’, as previously 
described by Simmonds et al.21 and Gomara et al.22. To confirm 
successful amplification of the targeted genomic area the prod-
ucts were checked (VP7, 881 bp; VP4, 660 bp) by electrophore-
sis in a 2% agarose gel. Products of samples that showed pres-
ence of the expected band size on gels were purified using 
GFX DNA purification kit (GFX-Amersham, UK) following 
the manufacturer’s instructions. These were then sequenced 
using Big Dye Terminator 3.1 (Applied Biosystems, Foster 
City, California, USA) chemistry and the same primers as in 
PCR amplification on an ABI Prism 3130xl Genetic Analyser 
(Applied Biosystems, Foster City, California, USA).
RVA genotyping and sequence analysis
The sequence reads were assembled into contigs using 
Sequencher version 5.4.6 (Gene Codes Corp Inc., Ann Arbor, 
MI, USA). The nucleotide sequences were aligned using MAFFT 
version 7.22223 and visualized in Aliview version 1.8 and 
further trimmed to remove sequence overhangs, resulting in 
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contigs of lengths between 480-660 bp (coordinates; 184-748) 
covering ~23% of the VP4 gene, and 486-854 bp (coordinates; 
460-824 of the VP7 gene) covering ~67% of the VP7 gene. 
G and P genotypes were determined using NCBI BLAST for 
sequences <500 bp (n=13 for VP4, n=5 for VP7) and the RotaC 
version 2.0 classification tool24 for sequences >500 bp. MEGA 
v7.0.26 was used to select the best maximum likelihood 
evolution models based on the Bayesian Information Criterion25 
(Supplementary Table 1) and reconstruction of maximum 
likelihood phylogenetic trees with 500 bootstrap replicates. Global 
contemporaneous sequences (2002–2013) (accession numbers in 
Supplementary File 1, lists 1 and 2) together with the Rotarix® 
vaccine strain sequences were retrieved from GenBank database 
and phylogenetically compared with the local sequences. Dupli-
cate sequences from the same country and non-overlapping 
sequences were removed. Clusters were identified based on high 
bootstrap values of >70% and high nt sequence similarity of >98%. 
Nucleotide and amino acid pairwise distances between the 
sequences were determined in MEGA v7.0.26. The trees were 
drawn to scale indicating nucleotide substitution rates per site.
Results
The prevalence of the genotypes and the circulation patterns 
described in this study were determined by use of all the data 
collected in 2002–2004 (phase I) surveillance period and all 
data collected between 2010–2013 (phase II). Data are available 
under restriction on Harvard Dataverse40.
RVA prevalence in KCH pediatric diarrhoea admissions
Over the 7-year surveillance period, a total of 3,779 stool sam-
ples were screened for RVA using EIA, of which 27.3% (n=1,031) 
tested positive. In phase I, the prevalence of RVA in the study 
population was 27.4% (n=558) while in phase II the preva-
lence was 27.2% (n=473) (Table 1). Sequencing was successful 
for 569 (76%) and 572 (77%) samples for the VP4 and VP7 
segments respectively (Table 1).
RVA genotypes in the study populations
The G genotypes identified in patients admitted at the KCH were 
G1-G3, G8-G10, G12, G29, while the P genotypes were P[4], 
P[6], P[8] and P[14] genotypes. Overall, G1P[8] was the domi-
nant strain at 51% followed by G9P[8] (15%), G8P[4] (14%) and 
G2P[4] (5%) as shown in Table 2 and Supplementary Figure 1. 
Strains G1P[4], G2P[8], G3P[4,6,8], G8P[6,8,14], G9P[4,6], 
G12P[4,6,8] were also detected, albeit in low frequency (<5%). 
The previous use of genotype-specific primers (rather than sequenc-
ing) to identify RVA strains in phase I enabled the detection of 
mixed infections in 8.2% of the cases; however, mixed infections 
were not seen when using sequence based methods. Additionally, 
9.2% of the samples were typed for only one of the two genes 
due to failure in sequencing and/or contig assembly (Table 2). 
G1P[8] predominated in all the years of phase I, while in phase II, 
this strain was dominant only in 2011 and 2013 (Figure 1A, B). 
Whilst strain G8P[4] was observed in low frequency in the 
whole of phase I, it was observed as the most common strain in 
2010 (46%) and 2012 (40%). Strain G9P[8] circulated in mod-
erate proportions, and was observed in all the years except in 
2013. Strain G2P[4] which was observed in low frequency 
in phase I (1.1%), was seen to increase in proportions in 
years 2010 (12%) and 2012 (23%). The rare strains, G1P[6], 
G2P[8] G8P[6] and G9P[6] were only observed in phase I, 
while the rare strains G3P[4,6], G12P[4,6,8], G10P[8] and 
G8P[14] were observed only in phase II. None of the rare 
strains observed in phase I became common in phase II.
Genetic relationship between RVA strains
Figure 2 shows the temporal frequency of genotypes G1, G2, 
G8, G9, P[4] and P[8] with their corresponding phylogenetic 
trees, while nucleotide pairwise difference within each geno-
type is shown in Supplementary Figure 2. The time period is 
split into 2002–2004, 2010–2011 and 2012–13 (shown by dif-
ferent colours) to facilitate temporal comparison. The G1 strains 
which were observed in all the years, formed clusters containing 
strains from both phase I and II, showing an overall sequence 
homology of >92% at the nucleotide level. Additionally, 
minor distinct clusters containing strains observed in phase II 
were also observed. The occurrence of G8 strains fluctuated with 
high prevalence observed in 2002, 2004 and 2010, and less prev-
alent in 2003 and 2009. Majority of the G8 strains showed high 
sequence homology of 96–100%, forming a common cluster 
including strains from both phases. However, a single sequence 
showed a decrease in homology up to 84% at nt level, and 
formed distinct clusters. The infrequently occurring G2 strains, 
formed two distinct clusters, where one cluster contained strains 
observed in phase II while the other had strains from both 
phases. Nevertheless, a high sequence homology of >95% at 
the nucleotide level was observed within G2 strains. Such high 
sequence homology was also observed in G9 strains, which 
were observed in high frequencies in all epidemic years except 
2013.
Table 1. A summary of diarrhoea cases, the number of samples tested, the proportion of RVA cases observed in the 
entire surveillance period and the number of samples sequenced from each phase from childhood admissions to 
KCH, Kenya, between 2002–2004 and 2010–2013.
Period Admissions, n Diarrhoea, n Samples 
tested, n
RVA 
cases, n
Proportion, % Sequenced, 
n (%)
Successfully 
assembled, n (%)
VP4 VP7
2002–2004 
(Phase I)
15347 3296 2039 558 27.2 272 (48) 192 (71) 218 (80)
2010–2013 
(Phase II)
11579 2260 1740 473 27.4 473 (100) 377 (80) 354 (75)
Total 26926 5556 3779 1031 27.3 745 (72%) 569 (76) 572 (77)
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Table 2. Frequency and proportions of RVA strains observed in Kilifi County Hospital between 2002–2004 and 2010–2013.
Type 2002 2003 2004 2010 2011 2012 2013 Total
n % n % n % n % n % n % n % n %
GP 
Genotypes
G1P[8] 90 (59) 79 (59) 63 (38) 19 (21) 101 (85) 16 (21) 28 (93) 396 51
G9P[8] 23 (15) 36 (27) 25 (15) 12 (13) 12 (10) 10 (13) 0 (0) 118 15
G8P[4] 3 (2) 7 (5) 28 (17) 42 (46) 0 (0) 30 (40) 0 (0) 110 14
G2P[4] 1 (1) 4 (3) 0 (0) 11 (12) 1 (1) 17 (23) 1 (3) 35 5
G8P[6] 17 (11) 1 (1) 15 (9) 0 (0) 0 (0) 0 (0) 0 (0) 33 4
G8P[8] 8 (5) 1 (1) 13 (8) 0 (0) 0 (0) 2 (3) 0 (0) 24 3
G1P[4] 0 (0) 0 (0) 10 (6) 3 (3) 0 (0) 0 (0) 0 (0) 13 2
G9P[6] 3 (2) 4 (3) 5 (3) 0 (0) 0 (0) 0 (0) 0 (0) 12 2
G1P[6] 3 (2) 0 (0) 6 (4) 0 (0) 0 (0) 0 (0) 0 (0) 9 1
G9P[4] 0 (0) 2 (1) 1 (1) 2 (2) 0 (0) 0 (0) 0 (0) 5 1
G2P[8] 4 (3) 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 6 1
G3P[8] 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 1 0
G12P[8] 0 (0) 0 (0) 0 (0) 1 (1) 3 (3) 0 (0) 0 (0) 4 1
G12P[4] 0 (0) 0 (0) 0 (0) 1 (1) 1 (1) 0 (0) 0 (0) 2 0
G3P[4] 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 0
G12P[6] 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 1 0
G3P[6] 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 0
G10P[8] 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 0
G8P[14] 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 1 0
Total 152 (100) 135 (100) 167 (100) 92 (100) 119 (100) 75 (100) 30 (100) 770 100
Mixed 
& Non 
Typable
Mixed 7 (27) 24 (71) 26 (59) 0 (0) 0 (0) 0 (0) 0 (0) 57 55
GNTP[4] 0 (0) 0 (0) 6 (14) 0 (0) 0 (0) 0 (0) 0 (0) 6 6
GNTP[6] 2 (8) 0 (0) 3 (7) 0 (0) 0 (0) 0 (0) 0 (0) 5 5
GNTP[8] 8 (31) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 9 9
G1PNT 5 (19) 5 (15) 2 (5) 0 (0) 0 (0) 0 (0) 0 (0) 12 12
G8PNT 1 (4) 1 (3) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 3 3
G9PNT 2 (8) 2 (6) 2 (5) 0 (0) 0 (0) 0 (0) 0 (0) 6 6
GNTPNT 1 (4) 2 (6) 3 (7) 0 (0) 0 (0) 0 (0) 0 (0) 6 6
Total 26 100 34 100 44 100 0 0 0 0 0 0 0 0 104 100
G1P[x] 0 (0) 0 (0) 0 (0) 0 (0) 7 (27) 2 (13) 7 (22) 16 16
Failed 
sequencing
G3P[x] 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (9) 3 3
G8P[x] 0 (0) 0 (0) 0 (0) 7 (26) 0 (0) 1 (6) 0 (0) 8 8
G9P[x] 0 (0) 0 (0) 0 (0) 0 (0) 2 (8) 1 (6) 0 (0) 3 3
G12P[x] 0 (0) 0 (0) 0 (0) 3 (11) 2 (8) 2 (13) 0 (0) 7 7
G29P[x] 0 (0) 0 (0) 0 (0) 1 (4) 0 (0) 0 (0) 0 (0) 1 1
GxP[8] 0 (0) 0 (0) 0 (0) 7 (26) 15 (58) 5 (31) 19 (59) 46 46
GxP[4] 0 (0) 0 (0) 0 (0) 9 (33) 0 (0) 5 (31) 3 (9) 17 17
Total 0 0 0 0 0 0 27 100 26 100 16 100 32 100 101 100
NT, non-typable; Gx and Px, undetermined G and P genotypes, respectively.
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Phylogenetically, the P[8] strains showed a close association 
among themselves with high sequence homology of >92% at nt 
level. Despite, the high homology, majority of the P[8] strains 
observed in phase I formed separate clusters from those observed 
in phase II. Unlike P[8] strains, P[4] strains occurred less 
frequently, with high prevalence observed in 2004 in phase I and 
2010 and 2012 in phase II. These strains formed three clusters, 
with one cluster containing both phase I and II strains while the 
other two clusters containing only phase II strains. Despite 
the distinct clustering, P[4] strains showed a high sequence 
similarity of 95–100% at the nucleotide level.
Phylogenetic placement of Kilifi strains in the global 
context
The placement of Kilifi strains in the global context is shown in 
Figure 3 and Figure 4. Tree clusters leading to Kilifi strains are 
Figure 1. Temporal distribution of RVA genotypes from positive RVA cases isolated from Kilifi County Hospital from 2002–2004 and 
2010–2013. (A) Annual proportions of the common genotypes. (B) The 4-month frequency of the commonly occurring genotypes. The colors 
represent the GP combinations as indicated on the legend of the plots. Genotypes that fall in the “Others” category in (A) represents those 
that occurred in low frequency <5%: G8P[8,14], G1P[4,6], G9P[4,6], G2P[8], G12P[4,6,8], G3P[4,6], G10P[8].
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Figure 2. Maximum likelihood phylogenetic trees of G1, G2, G8, G9, P[4] and P[8] genotypes inferred in MEGA v7, with taxa stratified 
in 3 groups, black for 2002–2004, green for 2010–2011 and red for 2012–2013, from viruses detected in childhood diarrhea admissions 
to KCH, Kenya. The bar graphs represent frequency of the same genotypes between 2002–2004 and 2010–2013. Only bootstrap 
values ≥70% are shown. This figure excludes the infrequent genotypes G3, G10, G12, G29 and P[6]. The scale bars indicate nucleotide 
substitutions per site.
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Figure 3. Maximum likelihood tree for VP7 G1 genotype showing the relationship between G1 genotypes from viruses detected in 
childhood admissions to KCH, Kenya, and to other global G1 genotypes detected between 2002 and 2013. Tree clusters (branches) 
including Kilifi strains are shown in the expanded boxes. Taxa for Kilifi strains are stratified in three groups, black for 2002–2004, green for 
2010–2011 and red for 2012–2013. Only bootstrap values ≥70% are shown. The scale bars indicate nucleotide substitution per site.
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Figure 4. Maximum likelihood tree for VP4 P[8] genotype showing the relationship between P[8] genotypes detected in childhood 
admissions to KCH, Kenya, and to other global P[8] genotypes detected between 2002–2013. Tree clusters (branches) including Kilifi 
strains are shown in the expanded boxes. Taxa for Kilifi strains are stratified in three groups, black for 2002–2004, green for 2010–2011 and 
red for 2012–2013. Only bootstrap values ≥70% are shown. Scale bar represents nucleotide substitutions per site.
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shown in the expanded boxes. A majority (85%) of the observed 
G1 strains, clustered away from the other global strains, cluster-
ing closely to strains detected in Africa, specifically in Kenya, 
South Africa and Togo. The second cluster comprised only 
strains from 2010–2012 which distinctively clustered with 
strains from Belgium and Ethiopia. The last clusters which had 
only single strains grouped together with strains from Japan and 
Pakistan. The Kilifi P[8], (Figure 5) strains were placed into 
four clusters, where the largest group comprised of Kilifi strains 
observed in both phase I and II, with external strains observed 
in Kenya, S. Africa, Tanzania, Ireland and Russia. The second 
cluster included Kilifi strains from phase I and II with strains 
from Belgium, Brazil and Ethiopia. The last minor clusters, each 
made of a single virus, showed a close similarity to strains 
isolated in Pakistan, Denmark, Ecuador and Belgium.
Phylogenetic analysis of the rare G8P[14] strain
Whilst several rare GP combinations (not commonly detected) 
were observed during the study period, G8 associated with 
a P[14] genotype has overall been rarely detected in human 
population26. Additionally, there has been an increasing number 
of human P[14] rotavirus strains globally, which are associ-
ated with rabbits, cattle, sheep and guanacos27. We therefore 
sought to investigate the probable origin of the observed G8P[14] 
detected in a 14 months old infant in 2010. All cognate sequences 
for genotypes G8 (n=71) and P[14] (n=47) isolated by 2013 
were retrieved from GenBank and phylogenetically compared 
to the observed genotypes. Duplicate sequences from strains 
isolated from the same country were removed. The G type in 
this samples (G8) clustered closely to other G8 strains iso-
lated from humans with a nucleotide and amino acid (aa) iden-
tity of 95% and 99%, respectively, and G8 strains isolated from 
camel showing a nucleotide and aa identity of 94% and 98%, 
respectively (Figure 5A). The P[14] genotype showed a high 
sequence similarity to other P[14] strains isolated from humans 
and bovine with a nucleotide similarity of 96% and 93% 
respectively and aa identity of 98% (Figure 5B).
Discussion
The present study provides insight into the molecular epidemi-
ology and phylogenetic relatedness of distant (7 years or more) 
and recent pre-vaccine introduction RVA strains detected in 
Kilifi, Coastal Kenya. This is the first detailed study on preva-
lence of RVA genotypes causing diarrhoea in children in rural 
coastal Kenya spanning over a decade before introduction of 
the nationwide routine RVA vaccination programme. The work 
builds on a previous study19, which highlighted the importance 
of genotypes G1, G8 and G9 in sub-Saharan Africa during the 
pre-vaccine introduction period. During phase I surveillance 
period, genotype-specific primers were used to characterize the 
strains into different G and P genotypes. In the present analysis, 
a fraction of phase I (46%) and all phase II RVA samples were 
sequenced and GP annotations assigned as per the guidelines 
of the Rotavirus Classification Working Group28.
In this analysis, strains G1P[8], G9P[8], G8P[4] and G2P[4] 
were the most common RVA strains, accounting for over 70% 
of the infections. These strains have also been observed in 
studies conducted elsewhere in Kenya29–31 and the world32,33. 
Genotype G8P[4] was the third most important strain after 
G1P[8] and G9P[8] accounting for 15% of RVA infections. The 
G8 genotype is mostly found in combination with P[4], P[6] and 
P[8] VP4 specificities34. In this study, the majority (83%) of the 
G8 strains combined with P[4] types, while only 16% combined 
with P[8] types. The increase in prevalence of this strain in phase II 
supports the notion of G8 strain regarded as an unusual and 
newly emerging strain in the world29,31. Genotype G3P[8] is also 
among the common genotypes causing infections in children, and 
is the second most important strain in Africa and fifth most impor-
tant globally32. Here, G3P[8] was detected at a low frequency, 
accounting for only 1% of all the cases. Genotype G12 
detection has increased in Africa and has also been observed in 
Kenya and for the first time in Kilifi (2010–2013).
The detection of atypical GP combinations; G1P[4, 6], G2P[6], 
G3P[4,6], G10P[8], and G8P[14], albeit at low levels, raises 
interest in their origins. Despite such atypical strains being less 
frequent, strains G3P[4] and G2P[6] were found to be the most 
important causes of diarrhoea in the late 1990s in Ghana35. Gen-
otype G10 has long been reported to infect calves, pigs or cat-
tle but recently has sporadically been reported in humans in 
several studies36,37. Similarly strain G8P[14] has recently been 
detected in humans and is thought to have originated from ani-
mals26,38. In this study, the close association of the observed 
strain G8P[14] with strains from both humans and animal origins 
shows a possibility of zoonotic transmission. The increase in diver-
sity of RVA in this setting could be attributed to the emergence 
of such unusual strains which might have arisen due to zoonotic 
transmission or re-assortment cases within and between RVA 
genotypes.
Post-vaccine surveillance studies have reported shifts in the 
prevalence of RVA genotypes. Recent post-vaccine introduc-
tion reports from Kenya have indicated an increase in preva-
lence of uncommon genotypes G3, G9 and G1239. Similarly, 
data from the USA depicted an increase in prevalence of G3P[8] 
in post-vaccine era relative to G1P[8] in the pre-vaccine period. 
In contrast, surveillance studies in Australia and Belgium 
revealed the dominance of G2 strains in post-vaccine period, 
relative to G1P[8] in pre-vaccine period. Similar studies in 
Ghana reported an increase in prevalence of G12P[8] and G10P[6] 
in the post-vaccine era. This shift in distribution of genotypes 
post-vaccine introduction might be associated with either selec-
tive vaccine pressure or the natural fluctuations of RVAs, although 
these are not evidently supported. The emergence of uncom-
mon genotypes and increased prevalence of non-vaccine strains 
warrants close monitoring to determine their circulation in the 
post-vaccine introduction period and their probable effect on 
performance of the vaccine.
Overall, the observed strains showed a high nucleotide sequence 
homology of up to 100%, as observed in the different geno-
types. The close genetic relationship of strains observed in 
phase I and phase II suggest a persistence in circulation of these 
RVA strains to continuously cause the observed epidemics. In 
addition, the exclusive clustering of majority of Kilifi strains 
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Figure 5. Maximum likelihood phylogenetic tree showing the relationship of the rare G8P[14] strain detected in a child admitted to 
KCH, Kenya, and, other similar strains detected in humans and animals retrieved from GenBank. (A) shows the phylogenetic relationship 
of the VP7 G8 genotype to other G8 genotypes. (B) Phylogenetic relationship of the VP4 P[14] genotype to other P[14] genotypes. Sequences 
for the strains identified in this study are marked by the black filled circle and the arrows. Only bootstrap values ≥70% are shown. Scale bar 
represents nucleotide substitution per site.
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from the global strains shows that theses strains might have been 
localized in Kilifi over a long period of time. However, few strains 
that formed three distinct clusters in both G1 and P[8] global 
trees, supports the notion of separate introductions and persist-
ence of possibly foreign strains in this setting. Although cases 
of re-assortment and possible introductions is evident, partial 
data from only two genes is insufficient in providing a complete 
understanding of the genetic diversity of such common and 
not common genotypes. Full genome sequencing will thus 
illuminate on the complete genomic constellations of these 
strains and provide data on their evolutionary dynamics. The 
marked seasonal and longer-term changes in genotype distribu-
tion observed in this pre-vaccine surveillance should be consid-
ered when interpreting changes to genotype patterns that may 
follow the introduction of rotavirus vaccine in any setting.
This study had several limitations, e.g. firstly, by use of partial 
sequencing method, we were unable to identify mixed infections 
in phase II, which were previously identified in phase I using 
other primer-based methods. Partial sequencing only identifies 
the dominant genotype in mixed infections resulting to one gen-
otype. The sequencing chromatograms of samples identified as 
mixed infections in phase I, appeared clean and mono-infected, 
with no background indicators of co-infections. Secondly, the 
classification of the strains into lineages and sub-lineages was 
limited due to the short consensus sequences, since only ~23% 
and ~67% of the VP4 and VP7 genes were sequenced, respec-
tively. Thirdly, it was not possible to perform comparative 
analysis of the rare genotype G29 due to unavailability of cog-
nate sequences in GenBank. Only a single reference sequence 
for genotype G29 had been deposited in GenBank by the time 
of this analysis.
In conclusion, this study shows that most of the pre-vaccine 
RVA infections and epidemics have been caused by a diverse 
range of RVA strains which fluctuated in prevalence from sea-
son to season, with some persistent in circulation for a long 
period. Additionally, new strains might have been introduced in 
this population and contributed significantly to the epidemics 
experienced in the pre-vaccine period. The recommendation by 
WHO for countries to vaccinate infants against rotavirus infec-
tion led to the inclusion of RotarixTM vaccine in the childhood 
immunization programme in Kenya. In addition to reducing 
hospitalization caused by RVA diarrhoea, the vaccine has been 
reported to offer protection against both homotypic and hetero-
typic RVA strains9. With the increase in diversity of circulating 
strains and emergence of rare strains in Kilifi, continuous moni-
toring will help evaluate the performance of this vaccine against 
the circulating strains.
Data availability
The replication data and analysis data for this manuscript are avail-
able from the Harvard Dataverse: https://doi.org/10.7910/DVN/
LVGYYW40.
Owing to data personal protection concerns, these data are 
restricted, but will be made available to researchers who meet the 
criteria for access to confidential data. Details of the criteria for 
sharing data and the conditions under which data are made 
available can be found in the KEMRI-Wellcome data sharing 
guidelines. Users who wish to use the data should send a 
request to the KEMRI Wellcome Trust Research Programme 
data governance committee, which can be contacted by emailing: 
dgc@kemri-wellcome.org.
Nucleotide sequence accession numbers
Partial sequences for the VP7 and VP4 genes reported in this work 
were deposited in the GenBank database under the sequential 
accession numbers MH402005-MH402781 and MH402782-
MH403560 for the VP7 and VP4 genes, respectively.
Grant information
The work was funded by GAVI (under the Rotavirus Immuniza-
tion Programme Evaluation in Kenya (RIPEK) study; a collabora-
tion between Emory University (USA), Centers for Disease Con-
trol and Prevention (CDC) in Atlanta USA, the Kenya Medical 
Research Institute (KEMRI)-Wellcome Trust Research Programme, 
Centre for Geographic Medicine Research-Coast, Kilifi, and the 
KEMRI Centre for Global Health Research (CGHR), Kisumu, 
Kenya). This work was also supported by the Wellcome Trust 
(203077; 102975). 
The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
Acknowledgements
We thank all study participants for their contribution of samples 
and data, and the KEMRI Wellcome Trust Research Programme 
colleagues for the useful discussions in preparation of the manu-
script. We thank the laboratory staff at KEMRI Wellcome Trust, 
Virus Epidemiology and Control Research Group for process-
ing of samples and initial lab analysis. We are grateful to Emory 
University which supported the work as part of the Rotavirus 
Immunization Program Evaluation in Kenya (RIPEK) led by 
Rob Breiman and funded by the Global Alliance for Vaccines 
and Immunization (GAVI). This paper is published with the 
permission of the Director KEMRI.
Supplementary material
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and 2010–2013. (a) Proportions of the most common VP7 G genotypes. (b) Proportions of the most common VP4 P geno-
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pie charts. The others category represents genotypes that circulated in low proportions. This included G3, 10, G12, G29 for panel a, P[6] and 
P[14] for panel b and G1P[4], G2P[8], G3P[4,6,8], G8P[6,8,14], G9P[4,6], G12P[4,6,8] for panel c.
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mixed genotypes. Authors should explain how mixed genotypes where determined and confirmed by
sequencing reaction.
3). The above data adds very little to the information we have on rotavirus genotypes circulating in Kenya.
I recommend that authors take this one step further, by performing a next generation sequencing on
selected genotypes. This will give the public more information on the interaction between the vaccine
strains and the wild type strains in Kenya.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Virology
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 09 Apr 2019
, KEMRI Wellcome Trust Reseach Program, KenyaMike Mwanga
Reviewer comment: Is the work clearly and accurately presented and does it cite the
current literature?  With the exception of citing genotype G12P[8] as the sixth most common
genotype in circulation, the authors have used recent and current citations. I would
recommend that authors edit the statement in paragraph 3 to include G12P[8].
Our response: We appreciate this correction and have modified the sentence (starting line
#31) to read "Globally, G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] have been identified as
the most common genotypes (in decreasing order) while G12P[6] and G12P[8] have
recently been reported as emerging genotypes.
 
Authors use a sequencing method to determine these genotypes. Reviewer comment:
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 Authors use a sequencing method to determine these genotypes. Reviewer comment:
With sequencing, you cannot call mixed genotypes. Authors should explain how mixed
genotypes were determined and confirmed by sequencing reaction.
Our response: We agree that our sequencing strategy could not support calling mixed
infections. This is a limitation we highlight in the discussion section of the manuscript. As
explained in the manuscript, the study was divided into two phases (I & II). In phase I
(2002-2014), genotyping was previously done using the PCR primer-based strategy 
. Phase II of the study usedhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923076/
sequencing to genotype. We have made this clear throughout the manuscript in this revised
version.
 
The above data adds very little to the information we have on Reviewer comment:
rotavirus genotypes circulating in Kenya.
Our response: We point out that our RVA genotypic and sequence data from Kenya
represents a large dataset in the period leading up to the vaccine introduction that spans a
wide time period. We feel this offers additional information than previously available by
which to explore patterns in one part of the country in a period spanning a decade to show
natural fluctuations and the extent of genetic diversity in circulating strains in the absence of
a vaccination programme. We further examined the global context of the local strains to
understand the nature of their source year-in-year-out. Additionally, to the best of our
knowledge, this is the first study in Kenya, to generate vast rotavirus partial seqence data
from a large sample set collected before vaccine introduction, hence an addition to the
limited sequence data for tracking RVA transmission. We believe that this study provides an
important baseline for future studies especially those attempting to interpret post-vaccine
introduction strain patterns.
 
 Reviewer comment; I recommend that authors take this one step further, by performing a
next-generation sequencing on selected genotypes. This will give the public more
information on the interaction between the vaccine strains and the wild type strains in
Kenya.
:Our response  We thank the reviewer for this suggestion. We are developing an in-house
NGS protocol but the results will form the basis of a separate publication.
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 Ernest Wandera Apondi
Kenya Research Station, Institute of Tropical Medicine, KEMRI/Nagasaki University, Nairobi, Kenya
Owor  conducted a longitudinal epidemiological study of rotavirus genotype distribution patterns inet al 
Coastal Kenya before the nationwide introduction of rotavirus vaccine. The authors employed methods
such as enzyme immunoassay (EIA) for the detection of group A rotavirus (RVA) and partial sequencing
of RVA positive samples in VP4 and VP7 segments for G and P genotyping. Data analysis reveals
remarkable genetic diversity of RVA strains circulating in this area, characterized by substantial
frequencies of unusual, mixed and emerging genotypes. Temporal fluctuation in RVA genotypes was
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 frequencies of unusual, mixed and emerging genotypes. Temporal fluctuation in RVA genotypes was
observed, with major shifts in G-P predominance involving G1P[8] and G8P[4].
The study was well conducted and the manuscript well written. The findings of this study are timely in light
of the recent introduction of rotavirus vaccine in Kenya and provide the baseline data necessary for the
assessment of vaccine effectiveness. This baseline data will also allow monitoring of RVA G and P
genotype changes that may alter vaccine effectiveness or that may be a result of vaccination, such as
possible breakthrough events under vaccine immune selective pressure.
Of noteworthy, a rare G8P[14] strain was detected in this study and the partial sequencing of this strain
indicated that its VP7 segment is closely related to humans and animals while its VP4 segment clustered
closely to that of human and bovine origin. Due to the unconventional nature of this and many other
uncommon strains detected in this study, it will be useful to sequence and characterize the full genomes
of the representative strains in order to provide important insights into their evolutionary dynamics.
Furthermore, since the uncommon strains, such as the ones detected in this study are either partially or
fully heterotypic to the currently licensed RVA vaccines (RV1 and RV5), vaccine effectiveness against
these strains needs to be closely monitored. 
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 09 Apr 2019
, KEMRI Wellcome Trust Reseach Program, KenyaMike Mwanga
We thank the reviewer for this appraisal of our work. We confirm that we are developing a whole
genome sequencing protocol to sequence a select group of positive samples. This will include
unusual strains and a longitudinal set spanning before to after introduction of the vaccine. The
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 genome sequencing protocol to sequence a select group of positive samples. This will include
unusual strains and a longitudinal set spanning before to after introduction of the vaccine. The
results will be presented in a separate publication. 
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